ArticleCell death & disease2026
CD70 drives cSCC growth by linking DNA damage response, inflammation, and tumor-stromal signaling.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Chronic ultraviolet (UV) exposure drives the development of non-melanoma skin cancers (NMSCs), particularly cutaneous squamous cell carcinoma (cSCC), through persistent DNA damage and inflammation. However, how UV-induced epithelial damage is coupled to inflammatory signaling and tumor-stromal communication during skin carcinogenesis remains incompletely understood. Here, we identify CD70, a TNF superfamily member, as a UV- and DNA damage-inducible regulator that links epithelial stress responses to stromal activation and tumor-promoting signaling. Integrative analyses of transcriptomic (GTEx, GSE2503, GSE42677), proteomic (RPPA), and immunostaining datasets reveal robust upregulation of CD70 in sun-exposed skin, actinic keratoses, and cSCC lesions. Functionally, CD70 silencing suppresses cSCC proliferation and xenograft growth, whereas solar UV or DMBA exposure induces CD70 expression. CD70 depletion disrupts cytokine-receptor signaling and MAPK/NF-κB pathways and alters inflammatory gene expression in UV-irradiated keratinocytes. In dermal fibroblasts, CD70 enhances NF-κB activation and secretion of IL-6 and MCP3 in TGF-β-activated fibroblasts, thereby reinforcing paracrine inflammatory loops that support cSCC spheroid expansion and tumor progression. CD70 knockdown in fibroblasts abrogates these effects and reduces tumor proliferation and cytokine expression in vivo. Mechanistically, E2F1 directly binds and activates the CD70 promoter, linking the DNA damage response to CD70 upregulation. Collectively, our findings identify CD70 as a stress-inducible signaling hub that links DNA damage, inflammation, and tumor-stromal communication in skin carcinogenesis. Targeting CD70 may disrupt this feed-forward inflammatory circuit and provide a therapeutic strategy for UV-driven and inflammation-associated cSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.